Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

BioTheryX

HQ: San Diego, CA source · biotheryx.com ↗

Clinical Phase 1

Keywords: oncology Breast Cancer Non Hodgkin Lymphoma Acute Myeloid Leukemia BTX-9341 BTX-1188

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jul 3, 2024 Trial start Phase 1: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer source ↗
Jan 24, 2022 Trial start Phase 1: A Study of BTX-1188 in Subjects With Advanced Malignancies source ↗

Upcoming milestones

Sep 30, 2027 (ESTIMATED) · Phase 1 · Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer · NCT06515470

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06515470	Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer	Phase 1	Recruiting	Jul 3, 2024	Sep 30, 2027 (estimated)
NCT05144334	A Study of BTX-1188 in Subjects With Advanced Malignancies	Phase 1	Terminated	Jan 24, 2022	Sep 12, 2023 (actual)